In a rigorous 18-week RCT, subjects with prediabetes taking inulin continued to lose significantly more weight during the unsupported maintenance phase (-2.3% vs -0.6%, p=0.012), demonstrating inulin's ability to sustain appetite suppression without ongoing clinical support - a hallmark advantage for long-term weight management.

RCT in healthy adults: 16 g/day inulin-type fructans (ITFs) significantly curbed appetite sensations including hunger and desire to eat compared to placebo. Inulin's fermentation produces short-chain fatty acids (SCFAs) that stimulate GLP-1 and PYY - the primary satiety hormones known to reduce food-seeking behaviour.

12-week RCT (n=125 overweight/obese adults): inulin-type fructans significantly reduced hunger, desire to eat, and prospective food consumption compared to control. Crucially, only ITF (not whey protein) altered gut microbiota - increasing Bifidobacterium - demonstrating inulin's unique dual mechanism of appetite control via both hormonal and microbiome pathways.

Chicory inulin (10 g/day for 2 months) significantly reduced fasting blood glucose and HbA1c in type 2 diabetic women - blood sugar stabilisation is one of the most potent and direct strategies for reducing carbohydrate cravings, since glycaemic spikes and crashes are a primary physiological driver of sugar addiction and compulsive snacking.

Inulin supplementation prevented obesity and significantly decreased endocannabinoid levels (anandamide and 2-AG) in the prefrontal cortex - a direct neurological mechanism linking inulin to food addiction. The endocannabinoid system governs reward-driven eating and food craving; inulin's ability to suppress this pathway suggests genuine anti-addictive potential.

Randomised crossover trial (n=48): oatmeal containing intact high-molecular-weight beta-glucan produced significantly greater appetite suppression than processed cereal over a 4-hour post-meal period, directly demonstrating that viscosity - driven by beta-glucan molecular weight - is the key determinant of satiety and energy intake reduction.

Meta-analysis of 4 RCTs (350 T2DM patients): oat beta-glucan (2.5-3.5 g/day for 3-8 weeks) significantly reduced fasting plasma glucose (-0.52 mmol/L, p=0.01) and HbA1c (-0.21%, p=0.03). Improved glycaemic control directly reduces the blood sugar fluctuations that trigger carbohydrate cravings and addictive eating cycles.

Meta-analysis confirming that daily beta-glucan consumption significantly reduces postprandial glucose and cholesterol. Flattening the postprandial glycaemic response is mechanistically critical: the glucose spike-and-crash cycle is a primary driver of hunger recurrence, sugar cravings, and the compulsive urge to eat between meals.

Comprehensive review of mechanistic pathways by which beta-glucan influences body weight: fermentation by gut microbiota produces propionate (the SCFA with strongest anorectic activity), stimulates release of cholecystokinin (CCK) and GLP-1, slows gastric emptying, and increases microbiome diversity - multiple converging pathways that suppress appetite and reduce energy intake.

High-barley beta-glucan diet significantly increased plasma PYY and GLP-1, reduced food intake, and improved insulin sensitivity through gut microbiota-produced butyrate. Significantly, these effects were abolished under germ-free conditions, proving the gut microbiome is the essential mediator - beta-glucan reshapes the microbiome to produce the very molecules that suppress appetite and craving signals.

Landmark study: guar gum (10 g twice daily) in obese subjects produced significant body weight reduction and significantly reduced daily hunger ratings over 10 weeks - superior to bran taken identically - while also improving insulin responsiveness. This remains one of the clearest direct demonstrations that guar gum reduces subjective hunger and drives weight loss through reduced caloric intake.

RCT in overweight men: guar gum addition to a meal blunted blood glucose peak-to-nadir swings and significantly increased satiety before the third meal. Moderating blood glucose dynamics is a direct mechanism for preventing the hunger rebounds and sweet cravings that derail weight management efforts.

Double-blind, cross-over RCT in obese women (n=25): hydrolysed guar gum significantly elevated post-meal cholecystokinin (CCK) - a primary gut satiety hormone that signals fullness to the brain and reduces meal size. CCK elevation is a proven mechanism for reducing the urge to continue eating beyond energy needs.

Review of all clinical evidence: partially hydrolysed guar gum (PHGG) at 2 g/serving produced significant sustained post-meal satiation and reduced inter-meal calorie intake by approximately 20% in normal subjects. At doses >5 g/day, PHGG reduced total daily energy intake. PHGG specifically stimulates CCK secretion and delays colonic transit - two mechanisms directly reducing the drive to snack between meals.

RCT in overweight men (n=28): modified guar gum added to a low-energy semi-solid meal prevented the appetite increase otherwise seen during caloric restriction - a critical finding showing guar gum can suppress the compensatory hunger response that undermines dietary weight loss and leads to binge eating and craving-driven relapse.

Meta-analysis of 13 RCTs (n=749): MCTs significantly reduced body weight (-0.51 kg), waist circumference (-1.46 cm), and hip circumference versus long-chain triglycerides. MCTs increased energy expenditure and fat oxidation - meaning the body preferentially burns fat rather than storing it, directly supporting fat mass reduction independent of caloric restriction.

Systematic review and meta-analysis (17 studies, 291 participants): MCT consumption produced a statistically significant moderate decrease in ad libitum energy intake compared to long-chain triglycerides - despite no measurable change in subjective appetite ratings. This dissociation suggests MCTs reduce food intake through a metabolic rather than a subjective hunger mechanism, offering a distinct pathway to calorie reduction.

28-day crossover RCT in overweight men: MCT-rich diet produced significantly greater loss of upper-body adipose tissue (-0.67 kg vs -0.02 kg for olive oil, p less than 0.05) and increased energy expenditure by 0.04 kcal/min. MCTs are almost entirely bypassed from adipose tissue storage - preferentially oxidised in the liver or converted to ketones, making them a uniquely non-fattening fat that supports body composition change.

Randomised crossover trial (n=29): MCT in liquid form reduced whole-day energy intake significantly versus LCT (7,904 vs 9,531 kJ; p=0.001) and delayed gastric emptying. Increased beta-hydroxybutyrate (ketones) from MCT provides an alternative brain fuel that reduces glucose dependence - directly addressing the physiological craving for quick-energy carbohydrates and sugar that drives addictive eating.

Real-world retrospective study (263 women): MCT supplementation (20 g/day) during ketogenic diet significantly enhanced fat mass loss compared to VLCKD alone. MCTs modulate ghrelin and PYY (hunger/satiety hormones), increasing ketone production which suppresses appetite via hypothalamic mechanisms - particularly relevant to reducing the intense hunger and cravings that typically accompany calorie-restricted weight loss.

Landmark RCT: pasteurised (heat-killed) A. muciniphila - acting as a postbiotic - improved insulin sensitivity by 28.62% (p=0.002), reduced insulinemia by 34% (p=0.006), and reduced body weight (-2.27 kg) and fat mass (-1.37 kg) compared to placebo. Crucially, the pasteurised form outperformed the live bacterium - establishing that it is the bacterial metabolites and cell wall components (postbiotic fractions) that drive the metabolic benefit.

Comprehensive review: postbiotics exert anti-obesity effects through increased energy expenditure, reduced adipogenesis, suppression of food intake, inhibition of lipid absorption, and regulation of gut dysbiosis. In clinical trials, heat-killed Lactobacillus amylovorus (CP1563), Bifidobacterium animalis subsp. lactis (CECT 8145), and Pediococcus pentosaceus (LP28) significantly improved body composition and anthropometric indices.

Comprehensive review of butyrate (a key SCFA postbiotic): animal studies strongly confirm butyrate positively affects adipose tissue metabolism, energy metabolism, systemic inflammation, insulin sensitivity, and body weight control. Butyrate regulates appetite by stimulating gut L-cells to release GLP-1 and PYY, crosses the blood-brain barrier to influence hypothalamic feeding circuits, and reduces the leptin resistance that causes persistent cravings in obese individuals.

Review demonstrating that butyrate (a postbiotic SCFA) positively affects energy homeostasis, behaviour, and inflammation in obesity. Individuals with obesity and T2DM show decreased butyrate-producing bacteria and downregulated butyrate production genes - establishing that postbiotic supplementation addresses a specific, measurable deficiency linked to the cravings, overeating, and metabolic dysfunction of obesity.

Review of all biotics and obesity: next-generation postbiotic strains Akkermansia muciniphila and Faecalibacterium prausnitzii have demonstrated the most promising results in weight reduction and metabolic parameter improvement. Postbiotics modulate gut microbiota via gut dysbiosis correction - restoring the balance of appetite-regulating hormones (ghrelin, leptin, GLP-1) that obesity disrupts, making them uniquely targeted anti-craving and anti-addiction tools.

3-week randomised controlled trial at Queen Margaret University, Edinburgh (n=28, mean age 34.5, BMI 25.05): pomegranate extract (Pomanox, 740 mg/day containing 210 mg punicalagin) versus placebo. Visual analogue scale measurements after breakfast and lunch showed the pomegranate group experienced significantly less hunger (p=0.044), greater fullness (p=0.02), and higher satisfaction (p=0.036), with an overall significant between-group difference (p less than 0.001). Crucially, pomegranate consumption was associated with significantly lower food intake during the satiety session compared to placebo - demonstrating that pomegranate polyphenols translate measured satiety improvements into objectively reduced eating behaviour. Note on GORA application: this study used a concentrated extract standardised to 210 mg punicalagin. GORA's 0.4 g pomegranate powder provides a lower polyphenol concentration, so the magnitude of effect is expected to be milder - but the direction of effect is scientifically substantiated within the same family of bioactive compounds. Included as supporting evidence for the role of pomegranate within the broader Mediterranean polyphenol matrix.